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Abstract
Alcohol-related liver disease is the most common alcohol-related medical 
illness, and it is the major driver of liver-related deaths worldwide. However, 
no screening guidelines currently exist for the early detection of liver disease in 
patients with risky drinking or those with alcohol use disorder. Moreover, most 
patients with alcohol-related liver fibrosis, which is the main prognostic factor of 
progression to end-stage liver disease, have normal blood tests. Abdominal ultra-
sound is a cheap and readily available diagnostic procedure that is rarely used in 
patients with alcohol use disorder without overt liver disease. In addition, abdomi-
nal ultrasound can detect other forms of liver disease, which are not uncommon in 
patients with unhealthy alcohol use, and can have a negative impact on the natural 
history of alcohol-related liver disease. In this chapter we will review the current 
knowledge about the use of liver ultrasound in patients with alcohol use disorder 
for the early detection of alcohol-related liver disease, as well as the potential use 
to detect other forms of liver disease. We will also briefly discuss other methods 
for the noninvasive detection of liver steatosis and/or liver fibrosis in patients with 
alcohol use disorder.
Keywords: abdominal ultrasound, alcohol-related liver disease, alcohol use disorder, 
liver steatosis; cirrhosis
1. Introduction
According to the last update of the Global Burden of Disease Study, alcohol con-
sumption is the seventh leading risk factor for both death and the burden of disease 
and injury [1]. Besides tobacco, alcohol accounts for a higher burden of disease 
than any other drug, and alcohol-related liver disease is the most common alcohol-
related chronic medical illness [2]. In recent years, there has been a worldwide 
increase in liver-related mortality due to end-stage liver disease [3], mostly because 
of the impact of alcohol consumption [4, 5]. With the recent advances in hepatitis B 
and C treatment, alcohol-related liver disease has become the main cause of liver-
related mortality [6].
It is important to note that, compared with other forms of liver disease, alcohol-
related liver disease has received little attention in the literature, as it is often 
stigmatized as a self-inflicted disease [7]. This is also true in clinical practice, as 
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alcohol use is often not properly screened or accounted for in medical charts, both 
in primary care and hospital settings [8], and treatment for alcohol use is offered to 
a minority of patients [2].
In this chapter, after a brief introduction about generalities of alcohol-related 
liver disease and about the assessment of alcohol use in patients with liver disease, 
we will discuss the current evidence for the use of abdominal ultrasounds in 
patients with alcohol use disorder (AUD). The current evidence includes a recently 
published Cochrane review and our own experience with the systematic perfor-
mance of abdominal ultrasounds in otherwise healthy adults with AUD admitted 
for hospital detoxification.
In addition, we will also discuss other potential benefits of the use of abdominal 
ultrasound to detect other forms of liver disease, which are not uncommon in 
patients with unhealthy alcohol use. We will address the use of liver ultrasound for 
hepatocellular carcinoma surveillance in patients with alcohol-related liver cirrho-
sis. Finally, we will include a brief mention of other available methods to screen for 
alcohol-related liver steatosis and alcohol-related liver fibrosis.
2. General overview of alcohol-related liver disease
Liver disease in patients with AUD encompasses a spectrum of histological 
abnormalities that includes steatosis, steatohepatitis, fibrosis, cirrhosis of the liver, 
and hepatocellular carcinoma [9, 10]. Those abnormalities, rather than being differ-
ent stages of the disease, can coexist in the same patient. Acute alcoholic hepatitis is a 
severe complication that can occur at any point in the course of alcohol-related liver 
disease and is associated with liver failure and with high short-term mortality [2].
Alcohol-related liver steatosis in the absence of alcoholic hepatitis is poten-
tially reversible with the cessation of alcohol consumption, but continued alcohol 
use is associated with progressive liver damage and an increased risk of alcoholic 
hepatitis [11]. Therefore, abstinence is advisable for patients with AUD and any 
form of alcohol-related liver disease, as it tends to diminish portal hypertension 
even in the more advanced forms of the disease [2]. Active alcohol consump-
tion is a formal contraindication for liver transplantation, which is of concern 
as alcohol-related liver disease is the leading cause of liver transplantation in 
Europe [12].
A timely diagnosis of liver disease in apparently asymptomatic patients with 
AUD contributes to a better prognosis and facilitates treatment [13, 14]. In patients 
with unhealthy alcohol use, liver damage is a major driver of disease burden, and it 
is often diagnosed in advanced stages, including decompensated liver cirrhosis [14]. 
In fact, nearly 75% of patients with liver disease present for the first time with a 
nonelective hospital admission due to end-stage liver disease [5].
The use of liver ultrasound is recommended by the current European guidelines 
to promote an early detection of nonalcoholic steatohepatitis [15]. However, no 
guidelines exist for the screening and early detection of liver damage in unhealthy 
drinkers, and screening approaches in this population are currently a matter of 
debate [16, 17].
Therefore, there is a need for screening and early detection of alcohol-related 
liver disease in patients who drink alcohol in excess, as it is well established that 
sharing abnormal findings suggestive of liver disease with patients can trigger 
behavioral change and decrease the use of alcohol [18].
Moreover, surveillance aimed to detect hepatocellular carcinoma in patients with 
alcohol-related liver disease is suboptimal, and liver cancer is often diagnosed at a 
later stage when potential curative treatments are futile [10].
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3. Assessment of alcohol use in patients with suspected liver disease
The Alcohol Use Disorders Identification Test (AUDIT) is a validated tool for 
identifying AUD in patients [19]. AUD encompasses both alcohol dependence and 
alcohol abuse [20], and represents the more extreme form of unhealthy alcohol use 
[21]. The use of AUDIT is recommended by both the American Association for the 
Study of Liver Diseases (AASLD) and the European Association for the Study of 
the Liver (EASL) guidelines [22, 23]. Other options are AUDIT-C (a shorter version 
of the AUDIT) [24], and the single-question screening tool that has been validated 
for the screening in primary care of unhealthy alcohol use, that is, the spectrum of 
alcohol use that goes from risky alcohol use to AUD [25].
Patients who screen positive for unhealthy alcohol use merit further assessment 
to rule out health consequences of alcohol with an emphasis on alcohol-related 
liver disease [2]. Besides laboratory testing, we believe that the performance of an 
abdominal ultrasound can be useful in this setting [17].
In addition, referral of patients to physicians who are specialists in addiction 
medicine is an option to increase the chances of successfully remaining abstinent [2].
4.  General overview of abdominal ultrasound for the study of liver 
diseases
Abdominal ultrasound is a cheap and widely available technique that is not usu-
ally performed to detect subjacent liver abnormalities in patients with AUD without 
overt liver disease.
4.1 Normal ultrasound findings of the liver
Abdominal ultrasound is an accurate method for estimating liver size, which 
should be determined at the midclavicular line and in normal conditions is less 
than 16 cm [26]. The liver parenchyma should be evaluated for focal and/or diffuse 
abnormalities. The normal liver appears as homogeneous with an echogenic texture. 
In normal conditions, liver echogenicity equals or slightly exceeds that of the renal 
cortex. This comparison heavily relies on the visual perception of the observer and 
on the presence (or absence) of disease processes in the renal cortex [27].
The right and left lobes, as well as the caudate lobe can be identified with the 
use of an ultrasound [28]. Other structures that should be identified are the main 
lobal fissure, which separates the left and right lobes and appears as an echogenic 
line that extends to the gallbladder fossa; the falciform ligament, which divides the 
left lobe into the medial and the lateral segments and appears as an echogenic area 
in the left lobe; and the ligamentum venosum, which separates the caudate from the 
left lobe and appears as an echogenic line anterior to the caudate lobe [28].
An abdominal ultrasound can also identify the major hepatic and perihepatic 
vessels, including the inferior vena cava (IVC), the hepatic veins, the main portal 
vein, and the right and left branches of the portal vein [28]. The main portal vein 
is characterized by thick and echogenic walls and enters the liver at the hilum. It 
divides into the right and left portal branches, and the left branch then divides 
into medial and lateral branches. The hepatic veins, which drain in the inferior 
vena cava, have thinner walls in comparison to the portal vein [28]. In addition, 
abdominal ultrasound is a reliable method for a first-line evaluation of portal vein 
abnormalities suggestive of portal hypertension [29]. It is also very useful to evalu-
ate the biliary tree and to detect ascitic fluid, and it can also be used to guide the 
performance of a paracentesis [28].
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Doppler evaluation should be used to document blood flow characteristics and 
blood flow direction, which is crucial in the diagnosis of portal hypertension [30]. 
In addition, Doppler evaluation can distinguish nodular lesions that are suggestive 
of hemangiomas, of hepatocellular carcinoma, or of liver metastases [31].
Figure 1 shows how a normal liver appears in an abdominal ultrasound.
4.2 Liver ultrasound in alcohol-related liver disease
In abdominal ultrasounds, liver steatosis appears as hyper-echogenicity due to the 
increased parenchymal reflectivity that intracellular fat accumulation produces [32]. 
The sensitivity of abdominal ultrasound to detect liver steatosis is impacted by the 
amount of fat content and severely decreases if fat content is lower than 10–20% [14].
The results about the ability of liver ultrasound to differentiate between liver 
steatosis and liver fibrosis have been mixed [33–35], and it is easier to differentiate 
when the degree of liver fibrosis is higher, as there is an increase in coarse echoes 
without posterior beam attenuation [32, 33, 36].
How to quantify liver steatosis with abdominal ultrasound is also a matter of 
debate. Liver steatosis is often classified as “mild,” “moderate,” or “severe” based on 
hyper-echogenicity, the discrepancy between echo amplitude in the liver and the 
kidney, impaired visualization of hepatic vessels, and loss of echoes from the walls 
of the portal system [36, 37].
Many authors consider steatosis to be mild if there is presence of hyper-echogenic 
liver tissue with fine and tightly packed echo targets and of normal beam penetration 
with normal visualization of the diaphragm and portal vein borders [38].
If there is decreased beam penetration with slightly decreased visualization of 
the diaphragm and the portal vein borders as well as moderate or diffuse increase of 
echo intensity, liver steatosis would then be considered to be moderate [38].
If there is a marked increase in echogenicity with no visualization of the portal 
vein border, an obscured diaphragm and posterior portion of the right lobe, and 
reduced visibility of the kidney, liver steatosis would be considered severe [38].
Figure 1. 
Normal liver.
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As mentioned in the introduction, different alcohol-related liver disease abnor-
malities can coexist in the same patient. Figure 2 shows an abdominal ultrasound 
consistent with severe steatosis in a patient with AUD admitted for hospital treat-
ment that also harbors a heterogeneous liver.
A potential weakness of liver ultrasound is operator dependency in assessing liver 
steatosis [27]. In a retrospective study that used static images of liver ultrasounds and 
included 168 patients from routine clinical practice and three independent radiologists, the 
mean inter-observer agreement rates for the presence of liver steatosis were 72%, while 
the mean intra-observer agreement 1 month later was 76% [27]. In that study, intra-
observer agreement for the severity of liver steatosis ranged from 55 to 68% [27].
In general, there is agreement that abdominal ultrasound is a cheap and reli-
able method to identify moderate or severe liver steatosis [38], but its accuracy 
for mild forms of steatosis is lower and may increase with the use of a computer-
aided method [38]. Besides liver steatosis, ultrasound findings that contribute to 
the detection of alcohol-related liver disease include (among others) liver size, 
Figure 2. 
Severe steatosis in an heterogeneous liver.
Figure 3. 
Heterogeneous liver in a patient with AUD admitted for hospital detoxification.
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bluntness of the edge, coarseness of parenchyma, nodularity of the surface, size 
of the lymph nodes around the hepatic artery, irregularity and narrowness of the 
inferior vena cava, portal vein velocity and caliber, and spleen size [28].
Figure 3 shows a heterogeneous liver in a 45-year-old patient with alcohol-
related liver disease, and Figure 4 shows an ultrasound of a 50-year-old patient 
with AUD and alcohol-related cirrhosis of the liver, as well as an enlarged portal 
vein, consistent with portal hypertension.
5. Use of liver ultrasound in patients with AUD: current evidence
Evidence about the use of liver ultrasounds to detect underlying liver disease 
in patients with AUD is scarce and includes a Cochrane systematic review and a 
recently published study by our group.
5.1 Cochrane systematic review
A Cochrane review published in 2016 stated that there was a need for studies 
of adequate sample size to study the efficacy of liver ultrasound in alcohol-related 
liver disease [39], as the review could only include two studies that aimed to assess 
alcohol-related liver cirrhosis with liver ultrasound [39].
The first study was published by French researchers in 1985 and included 126 
alcoholic patients who underwent liver ultrasound [40]. Of those, a hundred 
patients also underwent liver biopsy. The mean age of participants was 55.6 years. 
In that study, the main ultrasound findings were as follows: 100 patients (78%) pre-
sented hepatomegaly, 59 (46%) presented heterogeneous liver, 44 (34%) presented 
portal hypertension, and 82 (64%) presented liver cirrhosis. In those who under-
went liver biopsy, liver cirrhosis was confirmed in 72 participants, so ultrasound 
had a 81% sensitivity and 79% specificity for the detection of liver cirrhosis [40].
The second study was performed in Korea and published in 2013. It included 230 
patients (81% male) who underwent abdominal ultrasound and liver elastography 
prior to liver biopsy [41]. The mean age of the study population was 50.4 years; 199 
patients (86.5%) and 170 (74%) presented an ultrasound that was suggestive of 
Figure 4. 
Cirrhosis of the liver with an enlarged portal vein, consistent with portal hypertension.
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heterogeneous liver and liver cirrhosis, respectively. Liver cirrhosis was confirmed 
in 111 participants; therefore, ultrasound had a 94% sensitivity and 49% specificity 
for the detection of liver cirrhosis [41].
Due to differences in the selection criteria and the small number of patients 
included in both studies, the systematic review could reach no conclusion around 
the usefulness of liver ultrasound to detect underlying liver cirrhosis in patients 
with alcohol use [39].
5.2  Ultrasound findings of liver damage in a series of AUD patients consecutively 
admitted for hospital detoxification
We recently published a cross-sectional study of the use of abdominal ultra-
sound in 301 patients with AUD without overt liver disease that were admitted for 
hospital detoxification [17].
In that study, clinical and laboratory parameters were obtained at admission, 
and an abdominal ultrasound was performed on the third day of admission. 
Abdominal ultrasound was used to identify steatosis, hepatomegaly, heterogeneous 
liver, and portal hypertension. Portal hypertension was defined as having any of 
the following abnormalities: splenomegaly, enlarged portal vein, ascites, and/or 
abnormal portal vein flow.
For the purpose of the analysis, we defined analytical liver injury (ALI) as 
at least two of the following abnormalities: aspartate aminotransferase (AST) 
levels ≥74 < 300 U/L, AST/alanine aminotransferase (ALT) ratio >2, and total 
bilirubin>1.2 mg/dL. Advanced liver fibrosis (ALF) was measured with the FIB-4 
(a noninvasive index for the detection of liver fibrosis) [42], and was defined as a 
FIB-4 score ≥ 3.25.
We wanted to study bivariate associations of ultrasound abnormalities with 
three commonly observed conditions, hepatitis C virus infection (HCV), ALI, and 
ALF. We also used logistic regression to see if any of those three conditions pre-
dicted the presence of two or more ultrasound abnormalities.
In brief, 80% of the participants were male, with a median age of 46 years 
(Interquartile range [IQR]: 39–51 years) and had an alcohol consumption of 180 g/
day upon admission (IQR: 120–201 g). The prevalence of HCV was 21.2%; AST 
and ALT serum levels were 42 U/L (IQR: 23–78 U/L) and 35 U/L (IQR: 19–60 U/L), 
respectively; 16% of patients had ALI and 24% ALF. Ultrasound findings in the study 
population were as follows: 57.2% steatosis, 49.5% hepatomegaly, 17% heterogeneous 
liver, and 16% portal hypertension. Of note, 77% had at least one ultrasound abnor-
mality, and 45% had ≥2.
In logistic regression analyses, ALI and ALF were associated with having ≥2 
ultrasound abnormalities [Odds Ratio (OR) (95% Confidence Interval [CI]): 5.2 
(2.1–12.8), p < 0.01 and 4.7 (2.2–9.7), p < 0.01, respectively], while HCV infec-
tion was not (we performed a multivariate regression model for each of the three 
potential predictors) [17].
Most patients with only one ultrasound abnormality had hepatomegaly or mild 
to moderate steatosis, both of which represent morphologic changes that are poten-
tially reversible with alcohol cessation. Therefore, we believe that implementation of 
abdominal ultrasound in the regular care of patients seeking AUD treatment might 
be helpful for making clinical decisions and determining therapeutic interventions.
In fact, ultrasound abnormalities were very common in this series of patients, 
even in patients without HCV, ALI, and ALF, as only 31% of patients in that group 
had a totally normal abdominal ultrasound. In this regard, we believe that the use 
of ultrasound to detect early stages of liver disease may promote alcohol cessation, 
what might have a tremendous impact on the natural history of alcohol-related liver 
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cirrhosis, especially in patients that present earlier stages of the disease [17]. As 
previously described by other researchers, sharing findings that might impact nega-
tively the prognosis with patients may also be associated with a decrease in unhealthy 
drinking [18]. Upon publication of this study, a literature search did not identify any 
large ultrasound study of AUD patients with compensated liver disease [17].
5.3 Hepatocellular carcinoma surveillance
As mentioned before, hepatocellular carcinoma is the last stage of alcohol-
related liver disease, with an annual incidence of 2.9% in patients that already 
harbor liver cirrhosis [10]. It entails a very poor prognosis if not detected at the 
earliest possible stage [43]. This is the reason why all patients with alcohol-related 
cirrhosis should be included in hepatocellular carcinoma surveillance programs that 
typically consist of an abdominal ultrasound every 6 months [10].
However, periodical surveillance is not optimal in clinical practice, as surveillance 
is missed by one-third of patients and the interval between screening ultrasounds is 
often greater than 6 months [10]. In fact, less than 30% of hepatocellular carcinomas 
diagnosed in Europe and the USA are detected by surveillance [10, 44]. In addition, 
patients with alcohol-related liver cirrhosis are more likely to have deficient surveil-
lance than those with HCV infection [43, 45].
In our series of 301 patients with AUD that underwent liver ultrasound, 15 
(4.9%) had space occupying lesions; most of those lesions were hepatic hemangio-
mas, but hepatocellular carcinoma was diagnosed in 2 patients [17].
Figure 5 shows a liver nodule, suggestive of hepatocellular carcinoma over a 
cirrhotic liver in a 52-year-old woman with AUD and untreated chronic HCV.
5.4 Other potential uses of abdominal ultrasound in patients with AUD
Beyond the early detection of liver steatosis or liver cirrhosis, abdominal ultra-
sound might be useful for the detection of other forms of liver disease that may 
coexist with alcohol-related liver disease.
Alcohol use is common in patients with other forms of liver disease, and 
even alcohol use that would be considered moderate can be detrimental in these 
Figure 5. 
A liver nodule, suggestive of hepatocellular carcinoma over a cirrhotic liver in a 52-year-old woman with AUD 
and untreated chronic hepatitis C virus infection.
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situations [46, 47]. In fact, alcohol use is a cofactor for the progression of liver 
disease in patients with HCV, hepatitis B virus infection (HBV), nonalcoholic fatty 
liver disease, and hemochromatosis, among others. It is important to note that an 
arbitrary threshold of a daily alcohol intake of 30 grams for men and 20 grams for 
women is used to differentiate between alcohol-related liver damage and damage 
due to other etiologies [2]. However, with the current epidemic of overweight and 
obesity in Western societies, alcohol-related liver disease and nonalcoholic liver 
steatosis often coexist in the same patient [48]. In fact, in our cohort of patients 
with AUD that underwent abdominal ultrasound, the median body mass index was 
24.7 kg/m2, that is, a significant amount of patients were overweight [17].
In addition, the performance of abdominal ultrasound can detect less prevalent 
forms of liver disease, like vascular diseases (Budd-Chiari syndrome, hepatic vein 
congestion, and noncirrhotic portal hypertension) as well as other parenchymatous 
diseases.
6.  Other noninvasive procedures used to detect liver steatosis in patients 
with AUD
Controlled attenuation parameter (CAP) is a noninvasive tool to detect liver 
steatosis that measures ultrasound attenuation when trespassing fatty liver 
tissue [49]. CAP software is incorporated into the transient elastography equip-
ment, thus facilitating the bedside estimation of both liver steatosis and liver 
fibrosis [14].
In a recent individual patient data meta-analysis that included 2, 735 cases with 
both liver biopsy and CAP, cutoffs for moderate and severe liver steatosis were 
defined, with a diagnostic accuracy between 0.65 and 0.90 [50]. Patients included 
in that meta-analysis had mainly HBV (37%) and HCV (36%), or nonalcoholic fatty 
liver disease (20%), while patients with alcohol-related liver disease were underrep-
resented [50]. Given that all patients included in the meta-analysis harbored liver 
diseases that are strongly associated with liver fibrosis, there is a need for further 
validation of those cutoffs in a healthier population [51].
Another study by Thiele and colleagues published in 2018 that included 562 
patients with alcohol-related liver steatosis found that CAP above 290 dB/m ruled 
in any steatosis with 88% specificity and 92% positive predictive value, while CAP 
below 220 dB/m ruled out steatosis with 90% sensitivity, but 62% negative predic-
tive value [52]. Researchers concluded that CAP had a good diagnostic accuracy for 
diagnosing severe alcoholic liver steatosis and could be used to rule in any steatosis. 
The study also included a cohort of patients who were admitted for alcohol detoxifi-
cation and found that CAP rapidly declined in nonobese patients [52]. This finding 
speaks to the double-hit model of alcohol use and obesity in a significant proportion 
of patients commonly seen in clinical practice [53].
7.  Alternative noninvasive methods to detect liver fibrosis in patients 
with AUD
7.1 Transient elastography
Transient elastography has also been used for analyzing liver injury in patients 
with AUD. A study found elastography provided an assessment of fibrosis that was 
comparable to liver biopsy [16]. Other authors, however, have expressed concerns 
that alcohol-related steatohepatitis may distort results, leading to overestimation of 
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liver fibrosis in this population [54], especially in patients who maintain abstinence 
from alcohol, as liver stiffness seems to dramatically decrease with cessation of 
alcohol use [55].
A systematic review and meta-analysis published in 2016 that included 14 dif-
ferent studies suggested that transient elastography was a good method to exclude 
the presence of liver cirrhosis or advanced liver cirrhosis but advised that caution 
should be needed when using the same cutoffs described for viral hepatitis in other 
forms of liver disease [56].
A recently published individual patient data meta-analysis that included 1026 
patients suggested that cutoffs for transient elastography should be higher, espe-
cially in patients with elevated AST and/or bilirubin, suggestive of active alcoholic 
hepatitis [57].
Therefore, transient elastography is a promising tool, but it is mainly used in 
European countries in specialty clinics or teaching institutions [14]. In other coun-
tries its use is limited because of budget constraints or because it is only approved 
for research purposes.
7.2 Noninvasive laboratory-driven indices
There are several noninvasive indices to estimate liver fibrosis that are derived 
from laboratory parameters routinely used in clinical practice, including AST, ALT, 
and platelet count.
Among those, the most widely used are the FIB-4 [42], and the AST/platelet 
ratio index (APRI) [58], which have been validated against the gold standard of 
liver biopsy in HCV-monoinfected patients as well as HCV- and HIV-coinfected 
patients [59–61]. These indices perform better for detecting either the absence of 
liver fibrosis or the presence of advanced liver fibrosis [42, 58]. However, clinical 
experience using these markers in patients with AUD is somewhat limited [62]. In 
fact, some researchers have expressed concerns because of potential overestima-
tion of liver fibrosis when using these noninvasive indices in alcohol-related liver 
disease [62, 63].
In a series of patients with HIV and/or HCV infection, results around the ability 
of noninvasive indices to capture the impact of alcohol and liver fibrosis have been 
mixed, probably because of the different methods used to describe alcohol intake 
and other characteristics of the study population. A cross-sectional study in an 
urban cohort of HIV-infected individuals in Baltimore (USA) revealed that heavy 
alcohol use was associated with advanced liver fibrosis measured using the APRI 
score [64]. In that same study, when patients were stratified by HCV infection, high 
APRI score was associated with hazardous alcohol use only among patients without 
HCV infection [64]. In a cohort of HIV-infected women, Blackard and colleagues 
demonstrated that alcohol use was not associated with FIB-4 values among those 
with HCV-/HIV-coinfected women [65].
In a cohort of Boston HIV-infected patients with alcohol problems, lifetime 
alcohol consumption was not associated with the presence of advanced liver fibrosis 
(FIB-4 ≥ 3.25) [66, 67]. Another study performed in the Veterans Aging Cohort 
Study (VACS) reported greater risks of advanced liver fibrosis (measured with 
FIB-4) among HCV-/HIV-coinfected patients who exhibited any level of alcohol 
consumption or who had alcohol-related diagnoses [68].
Despite these somewhat discordant results, noninvasive markers of liver fibrosis 
have been widely used in populations with alcohol or other substance use disorders 
that are unlikely to undergo a liver biopsy [67, 69]. Besides, those noninvasive indices 
have been able to predict midterm mortality in epidemiological studies [69, 70]. A 
rather innovative approach is the combination of noninvasive indices and transient 
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elastography, so as to better characterize patients in the intermediate range of FIB-4 
values (1.45–3.25) [71].
8. Conclusions
Abdominal ultrasound is a cheap and easily available noninvasive method that 
could be useful as a first-line screening to assess underlying liver disease in patients 
with excessive alcohol intake. For patients that need further assessment, transient 
elastography and CAP, if available, might be helpful in defining the extent and 
magnitude of alcohol-related liver disease.
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